Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid
|
|
- Patrick Simon
- 7 years ago
- Views:
Transcription
1 Epidemiology of Hepatitis C Infection Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid
2 Worldwide Prevalence of Hepatitis C <1% 1% 2.4% 2.5% 4.9% 5% 10% >10% No data available WHO. Wkly Epidemiol Rec
3 Hepatitis C in Figures Worldwide prevalence 3% (170 M people) 1 Rate of chronification 75 85% 2 Rate of cirrhosis 10% in 20 years 20% in 30 years 2 Liver mortality (cirrhosis) 1 5% / per year 3 Hepatocarcinoma in cirrhotics 1 4% / per year 2 1. WHO. Hepatitis C. Fact sheet no CDC. MMWR CDC. Hepatitis C slide kit. September 25, 2000.
4 Distribution of Hepatitis C Genotypes 1a, 1b 2a, 2b, 3a 1a, 1b 2a, 2b, 2c, 3a 4 4 1b, 3a 2a 1b, 6 1b 1a, 1b, 2b, 3a 5a 3b 1b, 3a Fang et al. Clin Liver Dis
5 Distribution of HCV Genotype in the US Genotype 2, 3 22% Genotype 4, 5, 6 4% Genotype 1 74% Alter et al. N Engl J Med. 1999; Blatt et al. J Viral Hepatitis
6
7 HCV Prevalence by Selected Groups, US Hemophilia Injecting drug users Hemodialysis STD clients Gen population adults Surgeons, Nurses, PSWs Pregnant women Military personnel Average Percent Anti-HCV Positive Centers for Disease Control and Prevention
8 Prevalence of Hepatitis C by Age & Ethnicity, in the US 7 HCV-Ab positive (%) Blacks Whites =70 Age group (years) Hispanics Adaptado de Alter. N Engl J Med
9 Estimated Incidence of Acute HCV, U.S. New Infections/100, N~240,000/yr Decline in transfusion recipients Decline in injection drug users N~30, Year Centers for Disease Control and Prevention, 2005 Armstrong GL. Hepatology 2000;31: Alter MJ. Hepatology 1997;26:62S-65S
10 Prevalence of Hepatitis C in Spain Area Population (n) Prevalence* Author Year Cataluña General (2,154) 2.6% Sola 2002 La Rioja Urban (890) 2% Sacristán 1996 Galicia General (1,170) 1.6% Riestra 2001 Murcia General (2,203) 1% Gª-Fulgueira 1996 Zamora General (675) 0.7% Chimeno 2001 Alicante Drug addicts (832) 82% Esteban 1997 Madrid Immigrants 8.8% López-Velez 2003 Spain Estimated 2% *according to HCV-Ab positivity Around 70% of HCV-Ab positive are HCV-RNA positive
11 Prevalence of HCV infection in the United States 3,5 Risk factors 3 % 2,5 2 * * * * 1,5 1 0,5 0 Gender Socioeconomic Education Race males / females low-medium / high low / high others / white *p<0,05 Alter M. NEJM 1999
12 Prevalence of HCV infection in the US 6 5 Other risk factors * * Odds Ratio * >2 >50 * 0 *p<0.05 Marijuana Cocaine N sexual partners Early sexual intercourse Alter M. NEJM 1999
13 Exposures not associated with acquiring HCV infection Exposure Cases Controls (previous 6 months) (n=148) (n=200) Medical procedures 30.4% 29.5% Dental work 24.3% 23.5% Health care work (no blood contact) 4.1% 5.0% Ear piercing 2.7% 3.0% Tattooing 0.7% 0.5% Acupuncture 0 1.0% JID 1982;145:886-93; JAMA 1989;262:
14 Overlapping HCV & HIV epidemics HIV Hep C million 175 million million
15 HCV and HIV routes of transmission Percutaneous Injection drug use Transfusion, Transplant Therapeutic Occupational Permucosal Sexual Occupational Vertical Centers for Disease Control and Prevention
16 HCV and HIV in Figures in the US HCV HIV Incidence ,000 40,000 Prevalence 1, 3, M 0.94 M Deaths/year 1, 2, 5 8,000 10,000 15, CDC. Viral hepatitis C fact sheet. 2. CDC. HIV/AIDS Surveillance Report CDC. Viral hepatitis C fact sheet. 4. UNAIDS/OMS. AIDS epidemic update. 5. CDC. Viral hepatitis B frequently asked questions.
17 Danta M. CROI 2006 (abst 86)
18 Acute hepatitis C outbreaks in HIV+ MSM, UK Median number of different patners (12 months) * 20 Number * Cases (n=59) Controls (n=121) 5 0 Partners One-night stands *p<0.01 Danta M. CROI 2006 (abst 86)
19 Acute hepatitis C outbreaks in HIV+ MSM, UK Group sex risk factors % participating (12 months) * Group sex * Receptive UAI * Insertive UAI Receptive fisting * Insertive fisting * Drugs * Cases (n=52) Controls (n=63) UAI: unprotected anal intercourse; *p<0.01 Danta M. CROI 2006 (abst 86)
20 Prevalence of Chronic Viral Hepatitis in HIV Infected Patients 2,168 patients at the Hospital Carlos III Cohort 59% HCV alone HBV alone HCV+HBV HCV+HBV+Delta None 36% 1% 1% 3% Castellares, et al. J Hepatol (submitted)
21 Mean progression to cirrhosis among HIV+ is 25 years 3-fold faster in HIV pos than in HIV neg Fibrosis Grades (METAVIR Score) HIV+ (n = 122) Controls (n = 122) Duration of HCV Infection (years) Benhamou et al. Hepatology 1999 Soto et al. J Hepatol. 1997;26 :1-5
22 Fibrosis in Patients with Chronic Hepatitis C and Elevated ALT HIV negative (n=476) HIV positive (n=914) by biopsy (n=408) by elastometry F01 F2 F3 F4 Metavir Score 1 Forns et al. Hepatology 2002; 36: Martin-Carbonero et al. CID 2004; 38:
23 Risk of Cirrhosis and ESLD in HIV/HCV vs HCV alone Study N RR of Cirrhosis (95% CI) RR of ESLD (95% CI) Makris et al ( ) 10.8) 4.21 ( ) Soto et al ( ) -- Pol et al ( ) -- Benhamou et al ( ) -- Eyster et al (0.6-17) Telfer et al ( ) Lesens et al ( ) 25.5) Graham et al. 1, ( ) 6.14 ( )
24 Prevalence of Cirrhosis According to Liver Condition in HIV Infected Patients 2,168 patients at the Hospital Carlos III Cohort Cirrhosis (%) [95% CI] No. of patients 8.3 [ ] 19.2 [ ] 6.1 [ ] 41.7 [ ] 66.7 [ ] All HCV HBV HCV+HBV HCV+HBV +Delta 2, [ ] Alcohol 1.1 [ ] None/ Unknown 574 1,055 Castellares, et al. J Hepatol (submitted)
25 Chronic Hepatitis C: Mortality and Cumulative Costs Estimates for in the US Deats related Deaths due to CHC Cost 165,900 27,200 $10,700 M Wong et al. Am J Public Health
26 Impact of Chronic Hepatitis C in Coming Years ( ) Liver transplant 528% Liver decompensation Liver related deaths 223% 279% Hepatocarcinoma 68% Liver cirrhosis 61% Increase in 10 years (%) Davis et al. Hepatology
27 Liver Transplant in the US HCV related Other causes No. of patients Calendar year Kim. Hepatology
28 Chronic Hepatitis C Widely distributed Significantly prevalent in Western countries Frequently associated to HIV infection Source of clinical complications and mortality Impact on the health care system on the rise in coming years
The Epidemiology of Hepatitis A, B, and C
The Epidemiology of Hepatitis A, B, and C Jamie Berkes M.D. University of Illinois at Chicago jberkes@uic.edu Epidemiology: Definitions The study of the incidence and prevalence of diseases in large populations
More informationCase Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
More informationIncrease of sexually transmitted hepatitis C virus in HIV+ men who have sex with men in Barcelona, Spain. A problem linked to HIV infection?
Increase of sexually transmitted hepatitis C virus in HIV+ men who have sex with men in Barcelona, Spain. A problem linked to HIV infection? S. Manzanares-Laya 1, P. García de Olalla 1,2, C. Garriga 1,3,
More informationHepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL
Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment
More informationHEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
More informationNational Health Burden of CLD in Italy
National Health Burden of CLD in Italy 11,000 deaths due to liver cirrhosis or HCC in 2006 Direct costs for the National Health System for treating CLD patients: 420 M / year for hospital care 164 M /
More informationHepatitis C: Epidemiology, Transmission, and Screening. Jennifer Price, MD Assistant Professor of Medicine University of California San Francisco
Activity Code FA376 Hepatitis C: Epidemiology, Transmission, and Screening Jennifer Price, MD Assistant Professor of Medicine University of California San Francisco Learning Objectives Upon completion
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationPlacing Nation on the Path Toward the Elimination of Hepatitis C
Placing Nation on the Path Toward the Elimination of Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Division of Viral Hepatitis National Center for
More informationHepatitis C Virus Infection in Massachusetts: A tale of two epidemics
Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics Daniel Church, MPH Massachusetts Department of Public Health Bureau of Infectious Disease 1 Goals of presentation Provide an overview
More informationHepatitis C Infections in Oregon September 2014
Public Health Division Hepatitis C Infections in Oregon September 214 Chronic HCV in Oregon Since 25, when positive laboratory results for HCV infection became reportable in Oregon, 47,252 persons with
More informationViral Hepatitis A, B, and C
Viral Hepatitis A, B, and C What is Hepatitis? Hepatitis means inflammation of the liver Elizabeth A. Bancroft, MD, SM Acute Communicable Disease Control County of Los Angeles Department of Public Health
More informationJoão Silva de Mendonça, MD, PhD Infectious Diseases Service Hospital do Servidor Público Estadual São Paulo - Brazil
Brazilian Ministry of Health, Brazilian Society of Hepatology PAHO, Viral Hepatitis Prevention Board PART III SESSION 9 Prevention and control of Viral Hepatitis in Brazil HEPATITIS IN SPECIAL RISK GROUPS/
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationPREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
More informationEMERGING CLINICAL ISSUE: HEPATITIS C INFECTION IN HIV-INFECTED MEN WHO HAVE SEX WITH MEN
EMERGING CLINICAL ISSUE: HEPATITIS C INFECTION IN HIV-INFECTED MEN WHO HAVE SEX WITH MEN JUNE 2014 INTRODUCTION Approximately 3.2 million individuals in the United States are infected with chronic hepatitis
More informationHepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
More informationAre Booster Doses of Hepatitis B Vaccine Necessary?
Are Booster Doses of Hepatitis B Vaccine Necessary? Current CDC Recommendations And Gaps in Knowledge Division of Viral Hepatitis Centers for Disease Control and Prevention, USA Current United States Recommendations
More informationNew IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
More informationBURDEN OF LIVER DISEASE IN BRAZIL
BURDEN OF LIVER DISEASE IN BRAZIL Burden of Liver Disease in Europe Blachier et al. J Hepatol 58:593, 2013 Review of 260 epidemiologic studies of the 5 previous years Cirrhosis is responsible for 170.000
More informationRecommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965
Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationHCV Epidemiology in the United States
HCV Epidemiology in the United States Scott Holmberg, MD, MPH Chief, Epidemiology and Surveillance Branch, DVH, CDC sdh1@cdc.gov A Tale of Two Epidemics Chronic HCV: Rapidly increasing mortality and morbidity
More information2015 Outpatient Chronic Hepatitis B Management
2015 Outpatient Chronic Hepatitis B Management Hepatitis B Hepatitis B Info 70% of acute infections are subclinical More severe symptoms when in addition to other liver disease Fulminant Hepatitis
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationEpidemiology of HCV and HIV/HCV Infection in Guangzhou, China. Title. Charles Wang, M.D.
Epidemiology of HCV and HIV/HCV Infection in Guangzhou, China Title Charles Wang, M.D. Background Hepatitis C infects 170 million worldwide & 3 million Chinese HIV infects 33.3 million worldwide & 740,000
More information3/25/2014. April 3, 2014. Dennison MM, et al. Ann Intern Med. 2014;160:293 300.
April 3, 2014 3.6 million persons ever infected; 2.7 million chronic infections 1 Up to 75% unaware of status Transmitted through percutaneous exposure to infected blood Injection drug use (IDU) is the
More informationHIV Infection Among Those with an Injection Drug Use*-Associated Risk, Florida, 2014
To protect, promote and improve the health of all people in Florida through integrated state, county, and community efforts. HIV Infection Among Those with an Injection Drug Use*-Associated Risk, Florida,
More informationHEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
More informationHepatitis C Virus Infection: Prevalence Report, 2003 Data Source: Minnesota Department of Health HCV Surveillance System
Hepatitis C Virus Infection: Prevalence Report, 2003 Data Source: Minnesota Department of Health HCV Surveillance System P.O. Box 9441 Minneapolis, MN 55440-9441 612-676-5414, 1-877-676-5414 www.health.state.mn.us/immunize
More informationTHE A, B, C S OF HEPATITIS. Matt Eidem, M.D. Digestive Health Associates of Texas 1600 Coit Road Suite #301 Plano, Texas 75075 (972) 867-0019
THE A, B, C S OF HEPATITIS Matt Eidem, M.D. Digestive Health Associates of Texas 1600 Coit Road Suite #301 Plano, Texas 75075 (972) 867-0019 WHAT IS HEPATITIS? Hepatitis means inflammation of the liver
More informationSlide 1 HIV/ HCV Coinfected people: what are the specific concerns they face?
Slide 1 HIV/ HCV Coinfected people: what are the specific concerns they face? Marion Peters MD University of California San Francisco 2011 Slide 2 Special issues Effect of HIV on HCV Effects of HCV on
More informationPREPARED BY THE CENTER FOR HEALTH LAW AND POLICY INNOVATION OF HARVARD LAW SCHOOL
Pennsylvania PREPARED BY THE CENTER FOR HEALTH LAW AND POLICY INNOVATION OF HARVARD LAW SCHOOL Pennsylvania Hepatitis C Virus (HCV) in Pennsylvania Prevalence + + Although state-wide data were unavailable,
More informationBeginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice
Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice Dr Chris Ford GP & SMMGP Clinical Lead Kate Halliday Telford & Wrekin Shared Care Coordinator Aims Discuss:
More informationPreface. TTY: (888) 232-6348 or cdcinfo@cdc.gov. Hepatitis C Counseling and Testing, contact: 800-CDC-INFO (800-232-4636)
Preface The purpose of this CDC Hepatitis C Counseling and Testing manual is to provide guidance for hepatitis C counseling and testing of individuals born during 1945 1965. The guide was used in draft
More informationAfter the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
More informationWest Virginia HIV/AIDS Surveillance Report 2009 Update West Virginia HIV/AIDS Program
West Virginia HIV/AIDS Surveillance Report 2009 Update Bureau for Public Health Office of Epidemiology & Prevention Services Division of STD, HIV, & Hepatitis 350 Capitol Street, Room 125 Charleston, WV
More informationViral Hepatitis Case Report
Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date
More informationWilliam Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016
William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016 Advisory Committee on Immunization Practices (ACIP) The recommendations to be discussed are primarily those of the ACIP composed of 15
More informationEPIDEMIOLOGY OF HEPATITIS B IN IRELAND
EPIDEMIOLOGY OF HEPATITIS B IN IRELAND Table of Contents Acknowledgements 3 Summary 4 Introduction 5 Case Definitions 6 Materials and Methods 7 Results 8 Discussion 11 References 12 Epidemiology of Hepatitis
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationHEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationCo-infected health-care workers
Co-infected health-care workers Y.Yazdanpanah Service Universitaire des Maladies Infectieuses et du Voyageur C.H. Tourcoing, Faculté de Médecine de Lille CNRS U362, Lille, France Co-infected health-care
More information1.How did I get Hepatitis C?
1.How did I get Hepatitis C? Sharing needles and syringes ( iv drug use ) or using contaminated straws to snort cocaine Reused needles or medications in a health care setting- (LV endoscopy outbreak, glucometers
More information12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS
HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE DISEASE 101 ONLINE CONFERENCE SARAH WENINGER, MPH VIRAL HEPATITIS.STD.HIV PREVENTION COORDINATOR DECEMBER 3, 2015 OBJECTIVES Describe the populations that should
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationHepatitis C 1) THE DISEASE AND ITS EPIDEMIOLOGY
Hepatitis C June 2010 1) THE DISEASE AND ITS EPIDEMIOLOGY A. Etiologic Agent Hepatitis C (HCV) is caused by an RNA virus in the Flaviviridae family. Multiple HCV genotypes exist, with type 1 being most
More informationLong-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B
Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Patrick Marcellin Viral Hepatitis Research Center Hôpital Beaujon, University of Paris France OBJECTIVES OF THERAPY IN CHRONIC
More informationHepatitis C Virus (HCV)
HFS Report to Legislative Task Force Hepatitis C Arvind Goyal MD, MPH, MBA Medical Director Illinois Department of Healthcare and Family Services Hepatitis C Virus (HCV) Slowly progressive disease 40 years-median
More informationAppendix 3 Exposure Incident Report Form
Appendix 3 Exposure Incident Report Form January, 2015 Page 1 of 6 Please see the following pages for the Exposure Incident Report Form. Guidelines for the Management of Exposure to Blood and Body Fluids
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationPoor access to HCV treatment is undermining Universal Access A briefing note to the UNITAID Board
Poor access to HCV treatment is undermining Universal Access A briefing note to the UNITAID Board The growing crisis of HIV/HCV coinfection It is estimated that 4-5 million people living with HIV (PLHIV)
More informationGUIDELINES FOR VIRAL HEPATITIS SURVEILLANCE AND CASE MANAGEMENT
GUIDELINES FOR VIRAL HEPATITIS SURVEILLANCE AND CASE MANAGEMENT January 2005 Guidelines for Viral Hepatitis Surveillance and Case Management Ordering information To order a copy of this manual, write to:
More informationBoehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
More informationGuidelines for Viral Hepatitis CTR Services
Guidelines for Viral Hepatitis CTR Services During the 2007 North Dakota Legislative Assembly, legislation that called for the creation of a viral hepatitis program was introduced and approved. The North
More informationHIV Surveillance Update
HIV Surveillance Update Presentation to: CAPUS Metro Atlanta Testing and Linking Consortium (MATLC) Presented by: Deepali Rane, MPH and Jane Kelly, MD Georgia Department of Public Health Epidemiology Date:
More informationHepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm?
Hepatitis C David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham Substance Misuse Treatment in the West Midlands. How can we reduce harm? Birmingham October 19 th 2007 infection HCV Natural History
More informationwww.hepinfo.ie Are you Hep C aware? awareness information support prevention To find out more visit
Are you Hep C aware? awareness information support prevention To find out more visit www.hepinfo.ie What is Hepatitis C? Hepatitis C is a viral infection that affects the liver, causing it to become inflamed
More informationWhat to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning
More informationPositive impact of HCV treatment initiation on health outcomes in injecting drug users
Positive impact of HCV treatment initiation on health outcomes in injecting drug users Perrine ROUX, PhD Substance Use Research Center, Columbia University, NY Inserm U912, SE4S, Marseille Introduction
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationRisk Factors for Alcoholism among Taiwanese Aborigines
Risk Factors for Alcoholism among Taiwanese Aborigines Introduction Like most mental disorders, Alcoholism is a complex disease involving naturenurture interplay (1). The influence from the bio-psycho-social
More informationEfficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients
Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of
More informationStrategies to Improve the HCV Continuum of Care:
Strategies to Improve the HCV Continuum of Care: Best Practices in Testing, Linkage to Care & Treatment Ronald O. Valdiserri, M.D., M.P.H. Deputy Assistant Secretary for Health, Infectious Diseases June
More informationGeorgia HIV/AIDS Surveillance Summary. Data Through December 31, 2010
Georgia HIV/AIDS Surveillance Summary Data Through December 31, 2010 HIV/AIDS Epidemiology Section Division of Health Protection Georgia Department of Public Health Table of Contents Acknowledgements...
More informationGlobal Under Diagnosis of Viral Hepatitis
Global Under Diagnosis of Viral Hepatitis Mel Krajden MD, FRCPC Medical Head, Hepatitis Clinical Prevention Services Associate Medical Director, Public Health Microbiology & Reference Laboratory BC Centre
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationBriefing Note: Hepatitis B & Hepatitis C. Summary:
Briefing Note: Hepatitis B & Hepatitis C Summary: In Canada, hepatitis B and hepatitis C infections remain serious public health concerns due to high prevalence rates, high health care expenditures and
More informationMedical publications on HBV and HCV Coinfection
Recent advances of HBV and HCV co-infection 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師 2013.03.28 Outline Epidemiology of HBV and HCV coinfection Clinical significance of HBV and HCV coinfection Interplay between
More informationUsing Substance Abuse Prevention and Treatment (SAPT) Block Grant HIV Set- Aside Funds for Integrated Services
Using Substance Abuse Prevention and Treatment (SAPT) Block Grant HIV Set- Aside Funds for Integrated Services ADP Training Conference, Sacramento, August 21, 2012 Rachel McLean, MPH, CA Dept. of Public
More informationHEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015
CME ACCREDITED INTERACTIVE TRAINING SESSION: HEPATITIS C (HCV) @DDW 2015 LIVER DISEASE 905 891 1900 www.careeducation.ca info@careeducation.ca Community Academic Research Education @wearecare CME ACCREDITED
More informationNON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS Carl LeBuhn, MD Post-Exposure Prophylaxis (PEP) The use of therapeutic agents to prevent infection following exposure to a pathogen
More informationHepatitis C. Screening, Diagnosis and Linkage to Care
Hepatitis C Screening, Diagnosis and Linkage to Care Diagnosis If your hepatitis C antibody test is reactive, a second test will be needed to diagnose and determine if you are currently infected. Screening
More information2.5 Cancer of the liver
ALCOHOL CONSUMPTION 399 2.4.7 Effect modification The combined effects of smoking and alcoholic beverage consumption on the development of cancer of the oesophagus have been examined in several studies
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationInformation about hepatitis C for patients and carers
Information about hepatitis C for patients and carers What is hepatitis C? Hepatitis C is an illness caused by a virus which can be passed through blood from one person to another. It mainly affects the
More informationHepatitis C and pregnancy
Hepatitis C and pregnancy Assess HCV status at first visit Unknown HCV status If HCV + status based only on EIA +, order confirmatory RT-PCR Known HCV + status (RIBA or RT-PCR +) Hepatitis C Risk Factors
More information2011 STI Annual Report
STI Annual Report Howard Brown Health Center s third Annual STI Report details sexually transmitted infection (STI) and human immunodeficiency virus (HIV) testing and behavioral trends at many of Howard
More informationDisclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationLamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine
Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease From : New England Journal of Medicine Volume 351:1521-1531, Number 15, Oct 7, 2004 馬 偕 紀 念 醫 院 一 般 內 科, 肝 膽 腸 胃 科 新 竹 分 院 陳 重
More informationBloodborne Pathogens (HIV, HBV, and HCV) Exposure Management
Bloodborne Pathogens Exposure Policy and Procedures Employees of the State of South Dakota Department of Health Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management PEP Hotline 1-888-448-4911 DOH
More informationInjection Drug Users in Miami-Dade: NHBS-IDU2 Cycle Preliminary Results
Injection Drug Users in Miami-Dade: NHBS-IDU2 Cycle Preliminary Results David W. Forrest, Ph.D. Marlene LaLota, M.P.H. John-Mark Schacht Gabriel A. Cardenas, M.P.H. Lisa Metsch, Ph.D. National HIV Behavioral
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following
More information4/3/2012. Surveillance. Direct Care. Prevention. Quality Management
//1 The Epidemiology of Infectious and Chronic Diseases in Minority Communities December 7, 11 Mary G. McIntyre, M.D., M.P.H. Assistant State Health Officer for Disease Control and Prevention Alabama Department
More informationStrengthening the HCV Continuum of Care
Strengthening the HCV Continuum of Care Fabienne Laraque, MD, MPH, Medical Director Viral Hepatitis Surveillance, Prevention and Control Bureau of Communicable Diseases Control, NYC DOHMH March 18, 2014
More informationMedical Conditions and Health Care in Prisons
Medical Conditions and Health Care in Prisons Carla Conroy Stories are often showed on the news of convicted felons being sentenced to days, months and years in prison. What some people may not think about
More informationBACKGROUND MEDIA INFORMATION Fast facts about liver disease
BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of
More informationHEPATITIS C AND HIV: A GROWING THREAT TO UNIVERSAL ACCESS
Introduction In 2005, G8 leaders promised that by 2010 Universal Access to HIV prevention, treatment, care and support would be widely available. Since then, much has been accomplished and over 2 million
More informationHepatitis C in Colorado 2007 Surveillance Report Cases of Acute and Chronic Hepatitis C in Colorado
Hepatitis C in Colorado 2007 Surveillance Report Cases of Acute and Chronic Hepatitis C in Colorado Note: This report is published by the Viral Hepatitis Program (VHP), Disease Control and Environmental
More informationSeptember 17, 2010. Dear Secretary Sebelius:
September 17, 2010 Secretary Kathleen Sebelius Department of Health and Human Services Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, DC 20201 RE: Comments on OCIIO- 9992- IFC, Interim
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationHepatitis at a national level: government perspectives
Hepatitis at a national level: government perspectives Presenter: Dr Shin Young-Soo Regional Director WHO Western Pacific Panel The Honourable Dr. David Sergeenko Minister of Health, Labour and Social
More informationImpact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, 2004-2005. Tania Tang PHASE Symposium May 12, 2007
Impact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, 2004-2005 Tania Tang PHASE Symposium May 12, 2007 Presentation Outline Background Research Questions Methods Results Discussion
More informationWhen an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
More informationHepatitis C treatment update
Hepatitis C treatment update Viral Hepatitis Workshop Hepatitis Foundation and Regional Public Health December 2013 Jeffrey S Wong Hepatitis C treatment Non-A non-b hepatitis History of HCV treatment Hutt
More informationViral Hepatitis. 2009 APHL survey report
Issues in Brief: viral hepatitis testing Association of Public Health Laboratories May Viral Hepatitis Testing 9 APHL survey report In order to characterize the role that the nation s public health laboratories
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationGUIDELINES FOR THE MANAGEMENT OF HEPATITIS C
GUIDELINES FOR THE MANAGEMENT OF HEPATITIS C HEPATITIS, VIRAL A brief overview of hepatic viruses other than C - - The hepatitis A virus (HAV) infection is usually acquired by the fecal-oral route, produces
More information